The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances
Primary Purpose
Sleep Initiation and Maintenance Disorders
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Songha Night ®
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders
Eligibility Criteria
Inclusion Criteria:
- Psychophysiologic insomnia
- Severity: mild to moderate
- Duration: subacute to chronic
- Subjects age > 18 and < 65, men or women
- Subject had to give written informed consent
Exclusion Criteria:
- Regular use of psycho-active drugs
- Work in shifts
- Use of psychoactive drugs during the past 30 days
- Any treatment that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
- known hypersensitivity to any of the ingredients of the study drug
- Pregnancy, lactation, women of childbearing potential not using an established contraceptive
- Drug and alcohol abuse
- Participation in another trial within the past 30 days
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Songha Night ®
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change in sleep quality on a 100 mm visual analogue scale (VAS)
Secondary Outcome Measures
Feeling refreshed score (six point rating scale)
Ability to concentrate and perform well score (six point rating scale)
Night-time total sleeping time
Difficulty in falling asleep (five point rating scale)
Number of awakenings during the night
Physical and mental health state by short form (SF-36) questionnaire
Anxiety by State-Trait Anxiety Inventory
Frequency of adverse events
Global clinical impression on insomnia by short questionnaire
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02183714
Brief Title
The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances
Official Title
The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
May 1998 (undefined)
Primary Completion Date
December 1998 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
To evaluate the effect of Songha Night ® on insomnia, anxiety and quality of life compared to placebo in patients with mild to moderate insomnia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Initiation and Maintenance Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
146 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Songha Night ®
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Songha Night ®
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in sleep quality on a 100 mm visual analogue scale (VAS)
Time Frame
baseline, after 2 and 4 weeks of treatment, 1 week after end of treatment
Secondary Outcome Measure Information:
Title
Feeling refreshed score (six point rating scale)
Time Frame
up to week 5
Title
Ability to concentrate and perform well score (six point rating scale)
Time Frame
up to week 5
Title
Night-time total sleeping time
Time Frame
up to week 5
Title
Difficulty in falling asleep (five point rating scale)
Time Frame
up to week 5
Title
Number of awakenings during the night
Time Frame
up to week 5
Title
Physical and mental health state by short form (SF-36) questionnaire
Time Frame
up to week 5
Title
Anxiety by State-Trait Anxiety Inventory
Time Frame
up to week 5
Title
Frequency of adverse events
Time Frame
up to week 5
Title
Global clinical impression on insomnia by short questionnaire
Time Frame
up to week 5
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Psychophysiologic insomnia
Severity: mild to moderate
Duration: subacute to chronic
Subjects age > 18 and < 65, men or women
Subject had to give written informed consent
Exclusion Criteria:
Regular use of psycho-active drugs
Work in shifts
Use of psychoactive drugs during the past 30 days
Any treatment that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
known hypersensitivity to any of the ingredients of the study drug
Pregnancy, lactation, women of childbearing potential not using an established contraceptive
Drug and alcohol abuse
Participation in another trial within the past 30 days
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/582/582.1_U00-0003.pdf
Description
Related Info
Learn more about this trial
The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances
We'll reach out to this number within 24 hrs